Decades-long regulatory odyssey ends with FDA nod for Fabre-Kramer's depression med Exxua
Fierce Pharma
SEPTEMBER 28, 2023
Fabre-Kramer Pharmaceuticals' major depressive disorder (MDD) drug gepirone has been rejected by the FDA not once, not twice, but three times since the turn of the millennium. Fabre-Kramer's Exxua suffered three prior FDA rejections before scoring an FDA approval for major depressive disorder last week.
Let's personalize your content